



E-ISSN: 2278-4136

P-ISSN: 2349-8234

[www.phytojournal.com](http://www.phytojournal.com)

JPP 2020; 9(3): 1734-1738

Received: 01-03-2020

Accepted: 04-04-2020

**Gaurav Mude**Smt. Kishoritai Bhojar College  
of Pharmacy, Kamptee, Nagpur,  
Maharashtra, India**Shailesh Pise**Smt. Kishoritai Bhojar College  
of Pharmacy, Kamptee, Nagpur,  
Maharashtra, India**Kanchan Makade**Kamla Nehru College of  
Pharmacy, Butibori, Nagpur,  
Maharashtra, India**Rajshree Fating**Smt. Kishoritai Bhojar College  
of Pharmacy, Kamptee, Nagpur,  
Maharashtra, India**Seema Wakodkar**Kamla Nehru College of  
Pharmacy, Butibori, Nagpur,  
Maharashtra, India

## Potentiating effect of *N. Jatamansi* root extract by evaluating anti-depression and anxiolytic activity in rats

**Gaurav Mude, Shailesh Pise, Kanchan Makade, Rajshree Fating and Seema Wakodkar**

**Abstract**

Depression is considered as affective disorder characterized by change in mood, lack of interest in the surrounding. It is one of the mental health problems of people all over the world. Depression is a multifaceted condition characterised by episodes of mood disturbances alongside other symptoms such as anhedonia, psychomotor complaints, feelings of guilt and suicidal tendencies, all of which can range in severity. Anxiety and fear can be defined as response of subject to real or potential threats that may impair his/her homeostasis that can significantly mark function and quality of life. Some of depressive disorder overlap those of anxiety disorders, including severe phobias, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder. Anxiety-related disorders such as patient's nervousness, obsessive compulsive disorder and post-traumatic stress are foremost causes of infirmity in the world. Antidepressant and anxiolytic drug are the drug use for treatment of depression and anxiety but there are several side effect of these drug were observed like dry mouth, mental confusion, weakness and sedation. So, we evaluate the anti-depressant and anti-anxiety effect of *N. Jatamansi* root extract in rats by dose dependent manner. The behavior assessment observed by force swim test, locomotor activity, tail suspension test and elevated plus maze for depression and anxiety experimentation. The drug given 150mg/kg and 300mg/kg by oral route. The study observed that the ethanolic root extract reduced depression and anxiety generated by force swim test, tail suspension method, actophotometer and elevated plus maze.

**Keywords:** *N. Jatamansi*, depression, anxiety, obsessive compulsive disorder

**Introduction**

Depression and anxiety are two of the commonest psychiatric disorders worldwide (Ebmeier *et al.*, 2006; Kessler *et al.*, 2012, Silvia M *et al.*, 2019) [11, 23, 44]. Depression is one of the main mental health problems of people all over the world, and it is connected with many disabilities (Ren S *et al.*, 2015, Govindarajan VS *et al.*, 1982, Mohammad S *et al.*, 2015) [38, 17, 18, 30]. Depression is a multifaceted condition characterised by episodes of mood disturbances alongside other symptoms such as anhedonia, psychomotor complaints, feelings of guilt and suicidal tendencies, all of which can range in severity (Ebmeier *et al.*, 2006, Silvia M *et al.*, 2019) [11, 44]. It may range from a very mild condition, bordering on normality, to severe psychotic depression accompanied by hallucinations and delusions (Rang HP *et al.*, 2008, Mithun S *et al.*, 2011) [37, 29]. Major depression is distinguish by feelings of enormous sadness and despair, mental slowing and loss of concentration, pessimistic worry, lack of pleasure, self-deprecation, and variable agitation or hostility. Somatic changes also occur, particularly in severe, vital, or melancholic depression. These comprise insomnia or hypersomnia, altered eating motif, with starvation and slimming or sometimes overeating; decreased vitality and libido; and disruption of the normal circadian and ultradian tempo of activity, body reversal, and many endocrine functions (Tondo L *et al.*, 2003, Mithun S *et al.*, 2011) [46, 29]. The primary clinical reflexion of major depression are significant depression of mood and impairment of function.

Some features of depressive disorder overlap those of the anxiety disorders, including panicagoraphobia syndrome, severe phobias, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder (American Psychiatric Association., 2000, Mithun S *et al.*, 2011) [3, 29]. World Health Organisation, depression affects over 350 million individuals and is the global leading cause of disability (Smith, 2014; Greenberg *et al.*, 2015, Silvia M *et al.*, 2019) [45, 20, 44]. Anxiety-related disorders such as patient's nervousness, obsessive compulsive disorder and post-traumatic stress are the

**Corresponding Author:****Gaurav Mude**Smt. Kishoritai Bhojar College  
of Pharmacy, Kamptee, Nagpur,  
Maharashtra, India

foremost causes of infirmity in the world (Barua CC *et al.*, 2012) [8]. Currently, the most common approved medicines for anxiety disorders are benzodiazepines. Nevertheless, the medical uses of benzodiazepines are restricted by their side effects such as psychomotor destruction, potentiating activity of other sedatives and reliance liability (Latha K *et al.*, 2015, Mohammad S *et al.*, 2015) [26, 30]. It is a persistent illness that changes thoughts, mood and behavior of any person and has been expected to affect up to 21% population of the earth (Govindarajan VS *et al.*, 1982) [17, 18]. Synthetic drugs taken as antidepressant in proper dosages are regularly connected with their anticipated reactions like powerlessness in driving abilities, dry mouth, sexual brokenness and blockage and most of patients are hesitant to take this type of treatment (Govindarajan VS *et al.* 1982) [17, 18]. Consequently, natural plants may be potential sources of novel antidepressant drugs and the usage of plant extracts and their phytoconstituents may act as refined means in the management of depression and anxiety (Mohammad S *et al.*, 2015) [30].

*Nardostachys Jatamansi* (Family *Valerianaceae*) is widely used in several Asian countries as a bitter tonic, a stimulant and an antispasmodic, as well to treat epilepsy, hysteria, coria, palpitation and convulsion, also have been used to treat syncope an mental weakness (Bagchi *et al.*, 1991, Gi-sang B *et al.*, 2011) [6]. Various sesquiterpenes, such as jatamansic acid, jatamansone, lignance, and neoligance are present in the roots of plants (Aora RB *et al.*, 1965, chatterji A *et al.*, 1997, Gi-sang B *et al.*, 2011) [5, 10]. The species has very prolong history of use as medicine in ayurvedic, Homeopathic, ethno medicine and Indian System of Medicine (ISM) to modern medicinal industry which is dispense in the Himalaya from Pakistan, India (Jammu and Kashmir, Himachal Pradesh, Uttarakhand, and Sikkim) to Nepal, Tibet and China (Nayar MP *et al.*, 1988) [31]. It is acquire from wild and cultivated plant in Britain. The Netherlands, Belgium, France, Germany, Eastern Europe and Japan. Polyploidy occurs in *V. officinalis* and there are diploid, tetraploid, and octaploid type (Evans WC *et al.*, 2008, Purnima *et al.*, 2015) [13, 33, 34]. Sesquiterpenes and coumarins are present in considerable amount in the roots of *Jatamansi* plant mainly responsible for its essential oil (Chatterjee B *et al.*, 2005) [9]. It has protective effect in epilepsy, cerebral ischemia, liver damage (Ali S *et al.*, 2007 [2], Anonymous. The Wealth of India; vol2., 20010. Alcoholic extract of NJ are protective against thiacetamide-induced liver damage in rats (Bagchi *et al.*, 1991, Gi-sang B *et al.*, 2011) [6]. In Ayurveda, *N. Jatamansi* is used for headache, excitement, menopausal symptoms, flatulence, epilepsy and intestinal colic. In combination with cold water, the oil is considered to be effective against nausea, stomachache, flatulence, liver problem, jaundice and kidney complaints, insomnia and headache. Externally, it is used as oil in steaming bath to treat inflammation of the uterus. (Alam F *et al.*, 2016) [14, 15]. It has ben also used as herbal combination with other herb to evaluate depressant activity (Indurwade and Biyani 2000, Vidya S *et al.*, 2015) [22, 48]. The bimonthly treatment with an alcoholic root extract of *N. Jatamansi* caused an overall increase in the level of central monoamines and inhibitory amino acid, including a change in the level of serotonin, 5-hydroxyindole acetic acid, gamma-amino butyric acid and taurine in rat brain gives antidepressant action (Shastry Sd *et al.*, 1967, Firoj A *et al.*, 2016) [42, 14, 15]. For evaluating potentiating of *N. Jatamansi* we performed antidepressant and anxiolytic activity of extract.

## Materials and Method

### Materials

- Procurement of experimental animals:** The albino rats (Wister strain) of either sex weighing 150-200g, bred in the animal house of 'Kamla Nehru College of Pharmacy', Butibori, were procured. The animal were housed in polypropylene cages at a temperature of 25±2°C with relative humidity of 40-56% and 12 hrs.light dark cycle. Animal were fed with a balanced diet and water ad libitum during the complete experiments. All animal experiment were approve by the Institutional Animal Ethical Committee of Kamla Nehru College of Pharmacy, Butibori, Nagpur.
- Plant material collection and authentication:** The *N. Jatamansi* root were collected from Nagpur district, Maharashtra, India. The plant was identified an authenticated by "Post graduate" Teaching Department of Botany, Rashtrasant Tukadoji Maharaj, Nagpur University, Nagpur.
- Drugs and Chemicals:** Chemicals required for extraction and animal study was procured from institutional store. Distill water was used throughout the studies. The drugs and chemicals are listed below.

**Table 1:** Drugs and Chemical

| Drugs and Chemical | Source/Supplier                                   |
|--------------------|---|
| Diazepam           | Watson laboratories. Inc, Corona.                 |
| Imipramine         | West-ward Pharmaceuticals corporation.            |
| Ethanol            | Chagshu Hongsheng Fine Chemicals Corporation Ltd. |

### Methods

- Drying and size reduction of *N. Jatamansi* roots:** The dried roots of *N. Jatamansi* roots were dried in shed and powdered to #22 mesh size, stored in airtight container till further use (Purushottam K *et al.*, 2016)
- Soxhlet extraction of *N. Jatamansi* root:** The dried root of *N. Jatamansi* was coarsely powdered. 50gm of the powder was wrapped in a filter paper and put into a thimble with 500ml of 95% ethanol in a round bottom flask and subjected to Soxhlet for 6-8 hours. Dark brown solution of extract with alcohol was collected. Dark brown paste like extract was obtained after evaporation of alcohol (Purushottam K *et al.*, 2016).
- Dose preparation and administration of extracts:** The ethanolic extract of *N. Jatamansi* root was found to be non-toxic up to the dose of 200mg/kg and did not cause any death, therefore it is considered as safe. The biological evaluation was carried out at 150mg/kg and 300mg/kg dose level. The extract was concentrated on water bath at a temperature not exceeding 60 °C. The % Yield of the extract was 6%. Ethanolic extract of *N. Jatamansi* was administered at a dose of 150mg/kg and 300mg/kg orally (Purushottam k *et al.*, 2016).

| Sr. No. | Solvent       | Extraction Process | % Yield |
|---------|---------------|--------------------|---------|
| 1       | Ethanol (90%) | Soxhlet            | 6%      |

### Results:

#### Anti-depressant activity

- Forced Swim test:** The FST is the most widely used Pharmacological model for assessing antidepressant activity. The occurrence of immobility when the rodent

are put down in an inescapable cylinder of water through back the cessation of persistent escape directed behavior. The apparatus consisted of a clear Plexiglas cylinder (20cm high x 20cmdiameter) filled to 15 cm depth with water during test session the immobility time was recorded for 5 min, when the mice makes no further attempts to escape and make only movement to keeps it's above the water the water (Satish Rao *et al.*, 2013) [43].

2. **Tail Suspension Test:** The TST is the second method used for assessing the depressive state. A cord of about 50 cm in length was stretched between two metal tripods at a height of 70 cm tape. After the initial period of vigorous motor activity the mice became still and the immobility time was measured with a stopwatch, for a total duration of 5minute. Mice were considered immobile when the hung passively and completely motionless (Satish Rao *et al.*, 2013) [43].
3. **Locomotors activity:** The locomotor activity was measured by using actophotometer. The actophotometer consisted of a square area (30x30x25cm) with wire mesh bottom, in which the animal moves six light photocells were place in the outer periphery of the bottom such a way that a single mouse can obstruct only one beam. The movement of the animal interrupt a beam of light falling on photocell, at which a count was recorded and display

digitally. The locomotor activity was measured for a period of 10 minute. Technically its principle is that, a photocell is activated when the rays of light falling on the photocell are cut off by animal crossing the beam of light. As the photocell activated, a count is recorded. The photocells are connected to an electronic automatic counting device which count the number of 'cut off'.

4. **Elevated plus maze:** EPM test is the commonly used behavioral paradigm to assess the anxiolytic behavior in rodents. Briefly, the apparatus consisted of two open arms (5x5cm) and two closed arm (30x5x15cm) that extended from a common central platform (5x5cm). The entire maze was elevated to a height of 60 cm from the floor level (Lister, 1987). Testing was conducted in a quiet room that was illuminated only by a dim light. Each mouse was placed individually at the center of elevated plus maze with its head facing toward an open arm and its behavior was observed for a period of 5 minute using any maze software. During the test period, the number of entries into open arm, closed arm and time spent in each arm and percentage of time spent on the open arms was determined.

### Observations

#### Anti-depressant activity

**Table 2:** Force swim test

| Sr. No.                       | Body weight (gm) | Drug         | Dose (mg/kg) | Immobility time (Sec) | % Decrease in immobility |
|-------------------------------|------------------|--------------|--------------|-----------------------|--------------------------|
| <b>Vehicle (Control)</b>      |                  |              |              |                       |                          |
| Mean SEM                      | 178.2            | Control      | -            | 20.5                  | 100                      |
| <b>Treated (Standard)</b>     |                  |              |              |                       |                          |
| Mean SEM                      | 178              | Imipramine   | 2            | 9.5                   | 46.34                    |
| <b>Treated (N. Jatamansi)</b> |                  |              |              |                       |                          |
| Mean SEM                      | 180.5            | N. Jatamansi | 150          | 12.75                 | 62.19                    |
| Mean SEM                      | 184.25           | N. Jatamansi | 300          | 10.7                  | 48.78                    |

**Table 3:** Tail Suspension method

| Sr. No.                       | Body Weight (gm) | Drug         | Dose (mg) | Immobility Time (Sec) | % Decrease in Immobility |
|-------------------------------|------------------|--------------|-----------|-----------------------|--------------------------|
| <b>Vehicle (Control)</b>      |                  |              |           |                       |                          |
| Mean SEM                      | 177.5            | Control      | Saline    | 74                    | 100                      |
| <b>Treated (standard)</b>     |                  |              |           |                       |                          |
| Mean SEM                      | 178              | Imipramine   | 10        | 46                    | 62.16                    |
| <b>Treated (N. Jatamansi)</b> |                  |              |           |                       |                          |
| Mean SEM                      | 180.5            | N. Jatamansi | 150       | 63.25                 | 85.47                    |
| Mean SEM                      | 182.75           | N. Jatamansi | 300       | 50.25                 | 67.90                    |

**Table 4:** Locomotor activity

| Sr. NO.                       | Body Weight (gm) | Drug         | Dose (mg/kg) | Before Treatment | After Treatment | % Changes |
|-------------------------------|------------------|--------------|--------------|------------------|-----------------|-----------|
| <b>Treated (Standard)</b>     |                  |              |              |                  |                 |           |
| 1                             | 178              | Imipramine   | 10           | 41               | 61              | 173.17    |
| 2                             | 175              | Imipramine   | 10           | 68               | 88              | 129.41    |
| 3                             | 174              | Imipramine   | 10           | 52               | 72              | 138.46    |
| 4                             | 184              | Imipramine   | 10           | 69               | 89              | 128.98    |
| <b>Treated (N. Jatamansi)</b> |                  |              |              |                  |                 |           |
| 1                             | 176              | N. Jatamansi | 150          | 42               | 48              | 114.28    |
| 2                             | 183              | N. Jatamansi | 150          | 44               | 51              | 115.90    |
| 3                             | 186              | N. Jatamansi | 150          | 69               | 74              | 107.24    |
| 4                             | 177              | N. Jatamansi | 150          | 41               | 44              | 107.31    |
| <b>Treated (N. Jatamansi)</b> |                  |              |              |                  |                 |           |
| 1                             | 179              | N. Jatamansi | 300          | 40               | 69              | 172.05    |
| 2                             | 181              | N. Jatamansi | 300          | 66               | 85              | 128.78    |
| 3                             | 192              | N. Jatamansi | 300          | 50               | 60              | 120       |
| 4                             | 185              | N. Jatamansi | 300          | 68               | 86              | 126.47    |

**Anxiolytic Activity****Table 5:** Elevated plus Maze (EPM)

| Sr. No. |                 | Number of Entries |       | Time spent (sec) |       | % Preference to open arm |
|---------|-----------------|-------------------|-------|------------------|-------|--------------------------|
| 1       | Vehicle control | 8                 | 23    | 18               | 35    | -                        |
| 2       | Standard        | 15                | 20    | 30               | 48    | 166.6                    |
| 3       | NJEE (150mg/kg) | 11.25             | 13    | 20.5             | 146.7 | 113.6                    |
| 4       | NJEE (300mg/kg) | 14.5              | 12.25 | 28.5             | 140   | 158.3                    |

**Discussion**

*N. Jatamansi* is a vital herb with multiple remedies. It is an essential plant of Ayurvedic material medica. Present study states that the *N. Jatamansi* has numerous pharmacological activities, thereby enlarging the use of it. The study conducted was to evaluate the anti-depressant and anxiolytic activity of *N. Jatamansi* in rats to provide scientific evidence for its usage in the treatment of depression and anxiety. From the above results obtained the administration of ethanolic extract of *N. Jatamansi* in rats produced reduction of depression and anxiety in a dose-dependent manner. To determine whether there was a statistical difference in depression and anxiety achieved by the two doses (150 and 300 mg/kg). Orally administered, the data were compared with the standard (Diazepam and imipramine) group. The ethanolic extract of *N. Jatamansi* produced a significant reduction in depression and anxiety.

From the study observed that the ethanolic extract of the *N. Jatamansi* reduced depression and anxiety generated by forced swim test, tail suspension method, actophotometer and EPM.

**Summary**

Depression is considered as an effective disorder characterized by change in mood, lack of interest in the surrounding retardation and melancholia which is hilled by anti-depressant, anxiety and fear can be defined as the response of a subject to real or potential threats that may impair his/her homeostasis that can significantly mar the function and quality of life. *N. Jatamansi* study on the two groups having different concentrations of the drug *N. Jatamansi* (150 and 300 mg/kg). Animals were grouped as control standard and treated with *N. Jatamansi* (150 and 300 mg/kg). The instrument used for this is forced swim test, tail suspension method, actophotometer and EPM and the ethanolic extract of *N. Jatamansi* shows the anti-depressant and anxiolytic activity in the rat.

**Conclusion**

The findings of the present study suggested that the ethanolic extract of *N. Jatamansi* roots had anti-depressant and anxiolytic activity. It can be over that ethanolic extract of *N. Jatamansi* has dose-dependent anti-depressant activity and can also be used in patients suffering from depression due to sleep disturbances which also improve locomotor activity in sleep-deprived rats. So, *N. Jatamansi* will be an important plant to carry research for anti-depressant activity. The results from the study observed the anxiolytic properties of the herb in rats and suggest that the herb could serve as an approach in the treatment of anxiety.

**References**

1. Ali Rezaei, Mehrdad Pashazadeh *et al.* Comparative study of sedative and Anxiolytic Effect of Herbal Extract of *Hypericum Perforatum* with *Nardostachys Jatamansi* in Rats.

2. Ali S, Ansari KA, Jafri MA, Kabeer H, Diwakar G. N. *Jatamansi* protects Against liver damage by thioacetamide in rats. *J Ethnopharmacol.* 2007; 72:359-363.
3. American Psychiatric association. Diagnostic and Statistical Manual of mental disorders. Washington, DC: APA press, 2000.
4. Anonymous. The Wealth of India; National Institute of Science Communication; CSIR, New Delhi. 2001; 2:3-4.
5. Arora RB. *Nardostachys Jatamansi*- a chemical, Pharmacological and Clinical appraisal. Monograph special series. Indian Council of Medical Research, New Delhi, India, 1965, 5.
6. Bagchi A, Oshima Y, Hikino H. Neoligan and ligance of *Nardostachys Jatamansi* roots. *Plants Med.* 1991; 57:96-97.
7. Baghi A, Oshima Y, Hikino H. Validity of oriental medicines 142. Neoligans and ligance of *Nardostachys Jatamansi* roots. *Planta Medica.* 1991; 57:96-97.
8. Barua CC, Talukdar A, Begum SA, Borah P, Lakhar M. Anxiolytic activity of methanol leaf extract of *Achyranthes aspera* Linn in mice using experimental model of anxiety. *Indian J Pharmacol* 2012; 44:63-7.
9. Chatterjee B, Basak U, Dutta J, Banerji A, Neuman T. Prange Studies on chemical Constituents of *N. Jatamansi* *Cheminform.* 2005; 36:17.
10. Chatterji A, Pakrashi SC. The treatise on Indian Medicinal Plants. National Institute of Science Communication, New Delhi. 1997; 5:99-100.
11. Ebmeier KP, Donaghey C, Steele JD. Recent Development and current controversies in depression. *Lancet.* 2006; 367(9505):153-167.
12. Essential Medical pharmacology by KD Tripathi, 7<sup>th</sup> Edition, Jaypee Brother Medical publisher (P) Ltd, 439-451.
13. Evans WC. Trease and Evans Pharmacognosy, Edn 15, Published by Elsevier; Noida, India, 2008.
14. Firoj Alam, Vikas Kumar Chaudhari *et al.* A Phytochemical and Pharmacological Review on *Nardostachys Jatamansi* Dc. *Firoj Alam et al. IJCTPR.* 2016; 4(2):115-118.
15. Firoj Alam, Vikas Kumar Chaudhari, Pramod Kumar Biswal *et al.* A Phytochemical and Pharmacological Review on *Nardostachys Jatamansi* DC. 2016; 4(2):115-118.
16. Gaurav Solanki *et al.* Antianxiety Drugs an Overview.
17. Govindarajan VS. Ginger-Chemistry, Technology and quality evaluation: Part1. *Crit Rev Food Sci Nutr.* 1982; 17:1-96.
18. Govindarajan VS. Ginger-chemistry, technology and quality evaluation: Part2. *Crit Rev Food Sci Nutr.* 1982; 17:189-258.
19. Grant KL, Lutz RB. Ginger. *Am J. Health Syst Pharm.* 2000; 57(10):945-7.
20. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major

- depressive disorder in the United States (2005 and 2010). *J. Clin. Psychiatry*. 2015; 76(2):155-162.
21. Habibur Rahman, Muralidharan P *et al.* Comparative study of antidepressant activity of ethanolic extract of *N. Jatamansi* Dc Rhizome on Normal and sleep deprived Mice. *Der Pharmacia Letter*. 2010; 2(5):441-449.
  22. Indurwade NH, Biyani KR. Evaluation of Comparative and combined depressive effect of Brahmi, Shankpushpi and Jatamansi in mice. *Indian Journal of Medical science*. 2000; 54:339-341.
  23. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-Month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorder in the United State. *Int. J Method Psychiatric Res*. 2012; 21(3):169-184.
  24. Kotresh Y, Ramana MV *et al.* Anticonvulsant Activity of Methanolic Extract of Jatamansi Churna, ISSN No: 2277-7873, *IJPRS*. 2015; 4(4):129-134.
  25. Kourshsaki, Mahmoud Bahmani *et al.* The Effect of Most Important Medicinal Plant on two Important Psychiatric disorder (Anxiety and Depression)- A Review.
  26. Latha K, Rammohan B, Sunanda BP, Maheshwari MS, Mohan SK. Evaluation of anxiolytic activity of aqueous extract of Coriander *Sativum* Linn. In mice. A Preliminary experimental study. *Pharmacognosy Res* 2015; 7(1):47-51.
  27. Cotrim MD, Figueiredo IV *et al.* Behavioral test to Identify Anxiolytic activity of Drugs.
  28. Meda Ramesh, Jaya Shanakr Reddy V *et al.* A Review on Anxiolytic Activity of some Herbal Plants.
  29. Mithun Singh Rajput, Sampada Sinha, VinnetMahur, Purni Agrawal. *Herbal Antidepressant*. 2011; 1(1):159-169.
  30. Mohammad Shah Hafez Kabir, Mohammad Munawar Hossain, Md. Mominur Rahman *et al.* Antidepressant, anxiolytic and anti-nociceptive activities of ethanol extract of *Stuedneracolocasiifolia* K. Koch leaves in mice model. 2015; 3(11):890-894.
  31. Nayar MP, Sastry ARK. *Red Data Book of Indian Plants; Botanical Survey of India, Calcutta, 1998, 2.*
  32. Preeti, Milind Parle *et al.* Medicinal Plant possessing Anxiolytic activity: A Brief Review.
  33. Purnima Meenakshi Bhatt, Preeti Kothiyal *et al.* Phytochemistry and Pharmacological profile of *Nardostachys Jatamansi* Dc-Medicinal Herb, *Journal of Pharmacognosy and phytochemistry*. 2015; 3(5):102-106.
  34. Purnima, Meenakshi Bhatt, Preeti Kothiyal. A Review article on Phytochemistry and Pharmacologicak Profile of *Nardostachys Jatamansi* DC-Medicinal Herb. 2015; 3(5):103-106.
  35. Puroshotham K, Basavanna P *et al.* Anticonvulsant profile of *Nardostachys Jatamansi* in Albino rats. 2016; 5(3):758.
  36. Rajinder K Gupta *et al.* A Review on Spikenard (*Nardostachys Jatamansi* Dc) An 'Endagered' Essential Herb of India, *IJPC*. 2012; 2(3):52-60.
  37. Rang HP, Dale MM, Ritter JM, Flower RJ. *Pharmacology*. London: Churchill Livingstone Elsevier, 2008.
  38. Ren S, Wu M, Guo J, Zhang W, Liu X, Sun L *et al.* Sterilization of Polydimethylsiloxane Surface with Chinese Herb Extract. A new antibiotics mechanism of chlorogenic acid. *Sci. Rep*. 2015; 5:10464.
  39. Kulkarni SK. *Handbook of Experimental Pharmacology*. Vallabh Prakashan, Delhi, 2012.
  40. Sakina Razak, Farhath Khanum *et al.* Anxiolytic effect of *Nardostachys Jatamansi* Dc in mice, *Annals of Phytomedicine*. 2012; 1(2):67-73.
  41. Sanjay Singh, Nakoti, Divya Juyal *et al.* A Review on Pharmacognostic and Phytochemical Study of A Plant *Nardostachys Jatamansi*. *The Pharma Innovation Journal*. 2017; 6(7):936-941.
  42. Sastry SD, Maheshwari ML, Chakaravathi KK, Bhattacharya SC. Terpenoid CVI. The Structure of Calerenol Tetrahedron. 1967; 23:1997-2000.
  43. Satish Rao *et al.* Antidepressant Activity of *Nardostachys Jatamansi* in Electron Beam Irradiate Mice, 2013, 101-103.
  44. Silvia Muttoni, Maddalena Ardisson, Christopher John. Classical psychedelics for the treatment of depression and anxiety. A systematic Review, 2019, 11-24.
  45. Smith K. Mental health: a word of depression. *Nature*. 2014; 515(7526):180-181.
  46. Tondo L, Isacsson L. Baldessarini behavior in bipolar disorder; Risk and Prevention. *CNS Drugs*. 2003; 17:491-511.
  47. Jadhav VM, Thorat RM *et al.* Herbal Anxiolytic; *Nardostachys Jatamansi*. *Journal of Pharmacy Research*. 2009; 2(8):1208-1211.
  48. Vidya S Rao, Anjali Rao *et al.* Anticonvulsant and neurotoxicity profile of *Nardostachys Jatamansi* in rats, *Journal of Ethnopharmacology*. 2005; (102):351-356.